However, despite the multitude of clinical studies for the treatment of cancer, none of the targeted AKT inhibitors have reached phase III in clinical trials, reflecting the enormous complexity of AKT-signal-dependent malfunctions and potential adverse effects that have largely restricted the application and clinical significance of these inhibitors [35]. Here, AKT1 is linked to cancer.